Publications by authors named "Junko Toyoshima"

Claim this Profile
S
Single- and Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1128, a Novel Peroxisome Proliferator-activated Receptor δ Modulator, in Healthy Participants.
Yuta Taniuchi, J W Olivier van Till, Tomasz Wojtkowski, Junko Toyoshima, Akira Koibuchi

Clin Pharmacol Drug Dev· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Horizontal distribution of surface microplastic concentrations and water-column microplastic inventories in the Chukchi Sea, western Arctic Ocean.
Takahito Ikenoue, Ryota Nakajima, Amane Fujiwara, Jonaotaro Onodera, Motoyo Itoh, Junko Toyoshima

Sci Total Environ· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Junko Toyoshima, Atsunori Kaibara, Mai Shibata, Yuichiro Kaneko, Hiroyuki Izutsu

Pharmacol Res Perspect· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
Junko Toyoshima, Mai Shibata, Atsunori Kaibara, Yuichiro Kaneko, Hiroyuki Izutsu

Br J Clin Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tsuyoshi Kiyota

Clin Pharmacol Drug Dev· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
Akira Ono, Haruyasu Murakami, Takashi Seto, Toshio Shimizu, Sawori Watanabe, Junko Toyoshima

Drugs R D· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Junko Toyoshima, Masako Saito, Atsunori Kaibara, Hiroyuki Isaka, Taishi Sakatani

Clin Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Daisuke Miyatake, Tomohisa Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda

Clin Pharmacol Drug Dev· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Mai Shibata, Junko Toyoshima, Yuichiro Kaneko, Kazuo Oda, Tetsuya Nishimura

Eur J Clin Pharmacol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima

J Diabetes Investig· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Mai Shibata, Toshifumi Hatta, Masako Saito, Junko Toyoshima, Yuichiro Kaneko

Clin Drug Investig· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Masako Saito, Atsunori Kaibara, Takeshi Kadokura, Junko Toyoshima, Satoshi Yoshida

Diabetes Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, Junko Toyoshima

Diabetes Obes Metab· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Masako Saito, Atsunori Kaibara, Takeshi Kadokura, Junko Toyoshima, Satoshi Yoshida

Br J Clin Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kohei Kaku, Hiroyuki Isaka, Junko Toyoshima, Taishi Sakatani

Diabetes Obes Metab· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Hiroshige Mikamo, Kazuhiro Tateda, Katsunori Yanagihara, Shinya Kusachi, Yoshio Takesue, Junko Toyoshima

J Infect Chemother· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
Yuki Nomura, Hiromi Iitsuka, Junko Toyoshima, Kentaro Kuroishi, Toshifumi Hatta

Drug Metab Pharmacokinet· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.
Junko Toyoshima, Hiroyuki Kusuhara, Michael F Wempe, Hitoshi Endou, Yuichi Sugiyama

J Pharm Sci· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Sumito Ito, Hiroyuki Kusuhara, Miyu Yokochi, Junko Toyoshima, Katsuhisa Inoue

J Pharmacol Exp Ther· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis